BCAL Diagnostics Partners with US-Based Diagnostics Company; Shares Up 6%

MT Newswires Live

09/18

BCAL Diagnostics (ASX:BDX) partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in Australia and New Zealand, according to a Thursday filing with the Australian bourse.

The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.

The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.

BCAL Diagnostics shares rose 6% in morning trade on Thursday.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2568441729"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568441729\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568441729?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-18 09:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568441729","market":"sg","top_or_hot":-1,"title":"BCAL Diagnostics Partners with US-Based Diagnostics Company; Shares Up 6%","media":"MT Newswires Live","content":"<html><body><p> BCAL Diagnostics (ASX:BDX) partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in <a href=\"https://laohu8.com/S/AN3PF.AU\">Australia and New Zealand</a>, according to a Thursday filing with the Australian bourse.</p><p>The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.</p><p>The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.</p><p>BCAL Diagnostics shares rose 6% in morning trade on Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BCAL Diagnostics Partners with US-Based Diagnostics Company; Shares Up 6%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBCAL Diagnostics Partners with US-Based Diagnostics Company; Shares Up 6%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-18 09:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> BCAL Diagnostics (ASX:BDX) partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in <a href=\"https://laohu8.com/S/AN3PF.AU\">Australia and New Zealand</a>, according to a Thursday filing with the Australian bourse.</p><p>The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.</p><p>The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.</p><p>BCAL Diagnostics shares rose 6% in morning trade on Thursday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XKO.AU","symbol_name":"标普/澳交所 300指数","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568441729","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568441729","pubTimestamp":1758160198,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"BCAL Diagnostics  partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in Australia and New Zealand, according to a Thursday filing with the Australian bourse.The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.BCAL Diagnostics shares rose 6% in morning trade on Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XKO.AU":"标普/澳交所 300指数","BK4211":"区域性银行","BCAL":"Bank of Southern California NA","BDX.AU":"BCAL DIAGNOSTICS LTD","BK7067":"生物科技","XAO.AU":"标普/澳交所 普通股指数","XJO.AU":"标普/澳交所 200指数"},"translate_title":"BCAL Diagnostics与美国诊断公司合作；股价上涨6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCAL":1.5,"XJO.AU":0.82,"XKO.AU":0.82,"BDX.AU":1,"XAO.AU":0.82},"content_text":"BCAL Diagnostics (ASX:BDX) partnered with US-based ClearNote Health for the distribution of the latter's pancreatic and ovarian cancer blood tests in Australia and New Zealand, according to a Thursday filing with the Australian bourse.The agreement, set to begin in the first quarter of 2026, provides the company with rights to distribute and commercialize the tests and covers all future tests based on ClearNote Health's epigenomics testing platform, the filing said.The agreement is for an initial period of two years, with an option to extend for a further six years, according to the filing.BCAL Diagnostics shares rose 6% in morning trade on Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}